A large body of evidence indicates that up-regulated activity of the CRH system confers susceptibility for excessive self-administration of alcohol, and for relapse into alcohol seeking following abstinence. MTIP is a novel, orally available and brain penetrant CRH-R1 antagonist. Its activity in animal models predicts efficacy in alcohol dependence. Based on these findings, MTIP is a promising candidate for treatment of alcohol dependence.
